Skip to main content
PMC home page
Frontiers in Physiology logoLink to Frontiers in Physiology
. 2022 Mar 23;13:834716. doi: 10.3389/fphys.2022.834716

Mucus Clearance Strategies in Mechanically Ventilated Patients

Ryan L Goetz 1,†, Kadambari Vijaykumar 2,†, George M Solomon 2,3,*
PMCID: PMC8984116  PMID: 35399263

Abstract

The use of airway clearance strategies as supplementary treatment in respiratory disease has been best investigated in patients with cystic fibrosis (CF) and non-cystic fibrosis bronchiectasis (NCFBE), conditions which are traditionally characterized by excessive mucus stasis and mucociliary dysfunction. A variety of airway clearance therapies both pharmacological and non-pharmacological have been shown to ameliorate disease progression in this population and have hence been assimilated into routine respiratory care. This self-propagating cycle of mucus retention and airway damage leading to chronic inflammation and infections can also be applied to patients with respiratory failure requiring mechanical ventilation. Furthermore, excessive trachea-bronchial secretions have been associated with extubation failure presenting an opportunity for intervention. Evidence for the use of adjunctive mucoactive agents and other therapies to facilitate secretion clearance in these patients are not well defined, and this subgroup still remains largely underrepresented in clinical trials. In this review, we discuss the role of mucus clearance techniques with a proven benefit in patients with CF and NCFBE, and their potential role in patients requiring mechanical ventilation while highlighting the need for standardization and adoption of mucus clearance strategies in these patient populations.

Keywords: mucus clearance, mucoactive therapies, cough augmenters, mechanical ventilation, extubation failure

Introduction

Clearance of foreign particles and bacteria from the lungs is an important factor in host immunity, facilitated by the optimal functioning of the mucociliary system in conjunction with the cough reflex. The airway epithelium comprised of ciliated and secretory cells lines most of the conducting airways (Widdicombe and Wine, 2015). The secretory cells (including glands, goblet cells, and Clara cells) release various particles with antimicrobial and immunomodulatory properties including lysozyme, lactoferrin, proteases, and nitric oxide, in addition to mucins (Ganesan et al., 2013). Mucins (MUC5AC, MUC5B) are large adsorbent molecules binding water to form mucus and are believed to act as a scaffolding to protect and organize antimicrobial particles (Evans et al., 2010; Zanin et al., 2016). Disulfide bonds link these glycoproteins into large multi-multimers. Different subtypes of mucin have differing properties and predominate in different disease states (MUC5AC dominates in asthma; MUC5B dominates in chronic obstructive pulmonary disease (COPD) (Ehre et al., 2019). This resultant mucus layer coats the airways and adsorbs circulating particles and bacteria, which are propelled up by the cilia toward the oropharynx where it is swallowed (Wanner et al., 1996; Munkholm and Mortensen, 2014). When mucociliary clearance via ciliary mediated flow fails or is overwhelmed, cough is the next physiologic modality to propel particles, pathogens, and mucus out of the airways (Zahm et al., 1991; Knowles and Boucher, 2002).

There are two primary etiologies for a defective mucociliary clearance: dysfunctional cilia and dehydration of the airways. In primary ciliary dyskinesia (PCD) dysfunctional cilia fail to propel the mucus upward to the pharynx, while in CF dehydrated airways cause mucus to thicken with inability to be propelled up the airway to the pharynx (Chodhari et al., 2004; Fahy and Dickey, 2010). These genetic diseases represent severe examples of defective mucociliary clearance illustrating the principal of defective mucociliary clearance leading to recurrent infections (Chodhari et al., 2004; Fahy and Dickey, 2010).

Reduced mucociliary clearance has also been implicated in the pathogenesis of chronic airway infections, including: Pseudomonas aeruginosa (PsA), Haemophilus influenzae, and Staphylococcus aureus (Zhou-Suckow et al., 2017). PsA is the prototypical bacteria leading to chronic inflammation and defective mucociliary clearance via the release of proteases that induce epithelial damage and slow ciliary beat frequency (CBF) (Amitani et al., 1991). These chronic airway infections also lead to recruitment of neutrophils into the bronchial tree by a variety of different cytokines and chemotaxins, principally IL-8, and others including: IL-1β, tumor necrosis factor-α, and leukotriene B4 (Currie et al., 1987; Gaga et al., 1998; Mikami et al., 1998; Watt et al., 2004). Robust recruitment of inflammatory cells to the airways can lead to an inflammatory milieu in chronic lung diseases resulting in a cycle of overactive inflammation that actually impairs neutrophil phagocytic and killing function (particularly in PsA infection) (Berger et al., 1989; Hirche et al., 2008; King et al., 2009). This deficiency of airway clearance leading to chronic infections and inflammation has been referred to as the “vicious cycle” in CF and non-CF bronchiectasis (NCFBE), which is further perpetuated by an imbalance in repair and damage leading to destruction; a process that also likely occurs in mechanically ventilated patients (Cole, 1986).

Excessive tracheobronchial secretions along with an ineffective or weak cough have also been shown to be an important factor determining extubation failure in up to 89% of patients failing extubation or tracheostomy decannulation (Jaber et al., 2018; Maggiore et al., 2018). Evidence in support of airway clearance therapies for mechanically ventilated patients is sparse at best, underpinning the limitations for standardization of airway clearance protocols as a necessary part of routine care. In this review, we will explore mucus clearance techniques with proven benefit in patients with mucociliary disorders and explore their role in patients requiring mechanical ventilation.

Airway Clearance Deficits in Critically Ill Patients

Mucociliary dysfunction occurs both in acutely and chronically mechanically ventilated patients for a multitude of reasons. We define direct effects as those resulting directly from the mechanical ventilation circuit (including epithelial damage from endotracheal tube and cuff, anesthetics, lack of humidification, direct cough impairment) vs. indirect effects resulting from comorbid critical illness (inflammation, immobility, atelectasis) (Sackner et al., 1975a; Konrad et al., 1994). Anesthetic medications, specifically dexmedetomidine and ketamine, have been shown in in vitro models to directly decrease mucociliary clearance (Feldman et al., 2021). High FiO2 is known to decrease tracheal mucus velocity, likely through impaired ciliary function (Sackner et al., 1975b). Endotracheal tube cuffs, through direct epithelial damage, have also been known to impair ciliary function and decrease tracheal mucus velocity (Sackner et al., 1975a).

Recurrent pulmonary infections may act as a predisposition among these patients to further exacerbate mucociliary dysfunction (Pittet et al., 2010; Locke et al., 2016). Cough is similarly impaired due to mechanical prevention of glottic closure by the endotracheal tube (Smina et al., 2003). Moreover, cough is further impaired by relative immobility and weakness, leading to increased atelectasis and secretion retention in this population (Ray et al., 1974; Schweickert and Hall, 2007; Figure 1).

FIGURE 1.

FIGURE 1

Open in a new tab

Direct and indirect mechanisms contributing to mucociliary impairment in mechanically ventilated patients.

Treatment Modalities for Mucociliary Dysfunction in Critical Illness

A theoretical framework of deficiencies in optimal airway clearance leading to the self-propagating cycle of chronic infections and inflammation is described in Figure 2. The available evidence for mucus clearance modalities in mechanically ventilated patients can be divided into mucoactive therapies including expectorants and mucolytics, cough augmentation strategies including high frequency chest wall oscillation (HFCWO) vest, oscillatory positive expiratory pressure (ex: acapella/flutter valve), mechanical insufflation-exsufflation (MI-E); and therapies directly targeting inflammation and infection.

FIGURE 2.

FIGURE 2

Open in a new tab

Deficiencies in airway clearance lead to self-propagating cycle of chronic infections and inflammation. Mucolytics, e.g., N-acetylcysteine, hypertonic saline, dornase alfa; cough augmenters, e.g., use of intrapulmonary percussive ventilation, high frequency chest wall oscillation, mechanical insufflation- exsufflation devices.

Therapies Addressing Underlying Mucus Alterations

Chronic inflammation and infection commonly lead to mucus derangements in patients undergoing mechanical ventilation (including patients with endotracheal tubes and/or tracheostomies) (Konrad et al., 1994). Therapies targeted to address these alterations are typically grouped into two main categories: mucolytic therapies, which are utilized to decrease the viscosity of mucus, with a more liquid secretion leading to ease of suctioning; and expectorant therapies, which are utilized to hydrate the mucus and increase cough to assist clearance. Efficacy data from CF and NCFBE has led to the testing of n-acetylcysteine and dornase alfa as mucolytic therapy and hypertonic saline as expectorant therapy in mechanically ventilated patients (Shah et al., 2005; Rogers, 2007).

Nebulized n-acetylcysteine (NAC) functions as a mucolytic by severing disulfide bonds that link mucin oligomers (Rogers, 2007). In vitro studies have demonstrated that NAC rapidly decreases mucus viscosity, however, it may increase the risk of bronchospasm due its acidic pH (pH = 2.2) (Sheffner et al., 1964). This risk may be mitigated by pre-treatment with a bronchodilator or by utilizing a reduced concentration of NAC (10% as opposed to 20% concentration) (Henke and Ratjen, 2007). Use of oral N-acetylcysteine has been investigated in adults with non-CF bronchiectasis with a reported reduction in risk of exacerbations. 24.7% of the patients in N-acetylcysteine group compared to 11.3% of the control group remained exacerbation-free throughout the 12-month treatment period (P = 0.026). Additionally, the volume of 24-h sputum in the N-acetylcysteine group was significantly reduced (P = 0.002) (Qi et al., 2019). Other newer agents can also address these disulfide bonds, such as P3001. P3001 has a lower pKa of the active moiety and more rapid kinetics of disulfide bond reduction (Ehre et al., 2019). Data supporting use of NAC as a mucolytic in the mechanically ventilated population is limited. Use of nebulized NAC (2 mL of 20% NAC diluted within 8 mL of normal saline administered three times daily for 1 day) in a randomized controlled trial of 40 mechanically ventilated patients found a lower mean secretion density and increased oxygen saturation but failed to demonstrate superiority in comparison to normal saline nebulization (Masoompour et al., 2015).

Dornase alfa is a highly purified solution of recombinant human deoxyribonuclease-I (rhDNase), an enzyme which selectively cleaves DNA polymers (Rubin, 2014). Dornase alfa decreases neutrophilic airway inflammation resulting in reduced frequency of respiratory exacerbations and to improved pulmonary function in CF (McCoy et al., 1996; Quan et al., 2001; Paul et al., 2004; Ratjen et al., 2005). Few studies have explored the effectiveness of dornase alfa in mucus clearance in mechanically ventilated patients. In one pediatric study, 100 infants undergoing mechanically ventilation following cardiac surgery were randomized to dornase alfa and placebo arms. Although no difference was found in the primary outcome of reintubation, the trial demonstrated shorter time on mechanical ventilation, decreased atelectasis, and decreased ICU stay in the dornase alfa arm. The regimen utilized in this study was 0.1-0.2 mg/kg twice daily from time of surgery until extubation (Riethmueller et al., 2006). Youness et al. (2012) conducted a placebo controlled double blind trial of 33 adult mechanically ventilated patients with new onset lobar or multi-lobar collapse. Patients were randomized to 7% hypertonic saline (HTS), dornase alfa, or normal saline (NS). Therapies were administered twice daily for seven days or until complete resolution of atelectasis. There was no statistically significant difference between groups, but a trend toward improvement in atelectasis scores was appreciated in the dornase alfa group (reduction by 2.18 points in imaging score versus 1.09 and 1.00 in HTS and NS groups, respectively). While the authors did not posit a physiological hypothesis for this trend, there was concern for the lack of a standardized atelectasis scoring system which contributed to missing (14%) of the patient data, thus affecting the statistical analysis. However, this data suggests that complex mucus treated with potent mucolytics should be better explored for mucus plugging resulting in atelectasis and prolonged ventilatory failure. A randomized placebo-controlled, double-blind pilot study of 30 patients examined dornase alfa 2.5 mg twice daily compared to placebo in patients with new onset atelectasis in acutely mechanically ventilated patients. Patients were treated until extubation, death, or transfer up to 30 days. There was no difference in chest X-ray scores (primary outcome), however the intervention group did show improved oxygenation and more extubation on treatment day 1 (Zitter et al., 2013).

Hypertonic saline has been used as both a mucolytic and an expectorant, and has shown to decrease bacterial biofilm formation (Elkins and Bye, 2011; Rubin, 2014). In patients admitted with CF exacerbation HTS has also shown to decrease time to clinical improvement of lung function and significantly reduce symptom burden at discharge (Dentice et al., 2016). The use of HTS in patients undergoing mechanical ventilation has not been extensively investigated; however, it is commonly utilized in clinical practice. A study randomized 18 pediatric patients undergoing mechanical ventilation to nebulized 3% HTS versus 0.9% saline four times daily until seven days or until extubation in a prophylactic manner for secretions. This study found a greater duration of mechanical ventilation amongst patients receiving HTS (Shein et al., 2016). Patients randomized to HTS group had markers of greater illness severity at baseline when compared to NS. It was also notable that this therapy was administered prophylactically early in the disease course. In this population, we believe that there would be little in the way of benefit for HTS and that the differences in duration of mechanical ventilation likely represent baseline differences in the populations rather than treatment effect.

Few studies have explored a combination therapy of dornase alfa and HTS. The study from 2012 discussed above randomized patients to 7% HTS, dornase alfa, or normal saline. It found no statistically significant difference between HTS and normal saline in chest x-ray scores or oxygenation (Youness et al., 2012). A retrospective case control cohort study evaluated the use of 7% HTS and dornase alfa in mechanically ventilated neonates with atelectasis who were unresponsive to conventional airway clearance methods. Both medications were given twice daily. All treatment arms experienced greater improvement in atelectasis compared to control (27% in control group, 70% with HTS, 81% with dornase alfa, and 95% with combination therapy); however there was not a statistically significant difference between individual arms (Altunhan et al., 2012).

Data from meta- analysis of 4 mucoactive agents (including NAC, hypertonic saline, heparin, and ambroxol) across 13 randomized control trials have shown no effect on the duration of mechanical ventilation or hospital stay, but the analysis demonstrated a small effect on reducing ICU length of stay in the mucoactive agent groups (10 trials, 95% CI −5.49 to -0.96, I2= 89%) was appreciated (Anand et al., 2020).

Taken together, this data suggests that there is reason to utilize mucolytic and expectorant therapies in patients requiring mechanical ventilation, especially in those with excessive secretions and approaching extubation. However, the available evidence in critically ill patients is based on anecdotal data and expert recommendations, rather than validated studies, which limits drawing a definitive conclusion for the standardization of treatment regimens in critically ill patients. These trial data are summarized in Supplementary Table 1.

Cough Augmentation Strategies

In addition to the aforementioned deficits in airway clearance, cough and bulk mucus clearance are also altered in mechanically ventilated patients. Besides the mechanically prevented glottic closure, extensive and routine use of analgesics/sedative medications also suppress cough (Smina et al., 2003; Rosière et al., 2009). Impaired cough and excessive secretions notably have a prognostic significance for patients approaching liberation from the ventilator (Thille et al., 2015). Decreased and ineffective cough strength have also been associated with a higher risk of extubation failure (Thille et al., 2015; Gobert et al., 2017). A prospective, observational cohort study of 91 adult patients in medical-cardiac ICUs recovering from respiratory failure who passed a pressure support ventilation trial found that 89% of re-intubation cases have an excess of secretions vs. 39% of the successful extubations (Khamiees et al., 2001).

Cough assist devices, such as mechanical insufflation-exsufflation (MI-E), have also been explored in mechanically ventilated patients. Mechanical insufflation-exsufflation works on the principle that following deep inspiration with positive pressure, air in the lungs is expelled out immediately and rapidly by a forced negative pressure exsufflation. This resultant high pressure differential between the mouth and the alveoli creates a gradient to assist in the clearance of secretions (Homnick, 2007).

One single-center RCT of 180 adult ICU patients examined the use of MI-E in early mechanically ventilated patients which demonstrated improved secretion clearance (measured by weight of aspirated secretions) and lung compliance (Ferreira de Camillis et al., 2018).

High-frequency chest wall oscillation (HFCWO) involves oscillatory external chest wall compression causing expiratory flows that exceed inspiratory flow enhancing expectoration of mucus. In a pre-clinical canine model tracheal mucus transport was increased by 340% with HFCWO (King et al., 1983). This has resulted in the successful use of HFCWO in patients with CF and in patients with amyotrophic lateral sclerosis induced chronic respiratory failure (Warwick and Hansen, 1991; Lange et al., 2006). Use of HFCWO has mixed results in mechanically ventilated patients. In a recent study, 30 adult patients undergoing mechanical ventilation for acute respiratory failure were randomized to receive HFCWO or conventional chest physiotherapy (CCPT). In the HFCWO arm, patients had increased sputum weight, decreased atelectasis on imaging, improved oxygenation, and decreased tracheal culture positivity (Kuyrukluyildiz et al., 2016). Clinkscale et al. (2012) conducted a single center randomized trial that compared CCPT and HFCWO in a population including both mechanically ventilated and non-mechanically ventilated patients (CMVT). The study found no difference in length of hospital stay or duration of atelectasis but was underpowered for determining efficacy of either of these endpoints. Chuang et al. (2017) conducted a randomized trial of 73 patients mechanically ventilated for acute pneumonic respiratory failure comparing HFCWO and CCPT. They found decreased lower peak airway pressures following HFCWO, and higher oxygen saturations. This study was limited by methodologic concerns and multiple comparisons (Chuang et al., 2017). Additionally, a single center randomized study evaluating HFCWO vs. CCPT of 35 mechanically ventilated adults with COPD demonstrated a shorter total mechanical ventilation time in HFCWO group (10 days vs. 15) with no difference in invasive mechanical ventilation time, time in ICU or length of hospital stay (Liu et al., 2014).

Intrapulmonary percussive ventilation (IPV) is a newer modality in airway clearance. It generates “high flow mini-bursts of air along with a bronchodilator to the lungs at a rate of 300-400 times per minute”. This produces a higher pressure amplitude than unassisted modalities (e.g.; flutter valves and acapella devices) (Chatburn, 2007). IPV is commonly utilized in the outpatient setting in patients with CF and NCFBE (Natale et al., 1994). More recent studies have explored the use of IPV in mechanically ventilated patients. In a two-center RCT, 46 patients undergoing CMVT were randomized to IPV vs CCPT. After 15 days, the IPV group had significantly better oxygenation, higher maximal expiratory pressure, and a lower incidence of nosocomial pneumonia (Clini et al., 2006). A crossover study of 8 chronic tracheostomy patients (age 1-22 years) comparing IPV and HFCWO across various time periods showed significant reduction in the number of respiratory infections, need for systemic steroids, and hospitalizations with IPV (Bidiwala et al., 2017). Use of IPV was also evaluated in 10 obese mechanically ventilated patients with atelectasis in a retrospective case series which demonstrated improved oxygenation and lung compliance compared to case controls not receiving IPV (Tsuruta et al., 2006).

Taken together, this data suggests equipoise regarding the use of chest physiotherapy and other cough augmentation strategies, but there is insufficient data to conclude that any single modality is superior. These data are summarized in Supplementary Table 2.

Modalities Directly Targeting Infection and Inflammation

Macrolide antibiotics are associated with a host of anti-inflammatory and immuno-modulatory effects achieved through multi-factorial mechanisms. One of the more commonly described pathways involves blockade of IL-8, leading to decreased airway neutrophil recruitment and neutrophil elastase elaboration (Verleden et al., 2006). Macrolides also reduce IL-1β concentrations, TNF- α, and IL-6 both in plasma and lung tissue. In mechanically ventilated patients, one RCT explored the role of azithromycin in PsA colonized patients undergoing mechanical ventilation and found a non-significant decrease in the incidence of VAP. Post hoc analysis showed greater decrease in VAP in patients with PsA strains with quorum sensing-dependent virulence factors (van Delden et al., 2012). A larger study randomized 200 patients with VAP to clarithromycin for 3 days vs. placebo (in addition to standard anti-microbial therapy determined by treating clinician). They demonstrated improved time to clinical resolution, reduced duration of mechanical ventilation, and delayed onset of multi-organ dysfunction (Giamarellos-Bourboulis et al., 2008). An analysis of cytokine levels during this study demonstrated an improved balance between pro-inflammatory versus anti-inflammatory mediators in patients treated with clarithromycin (Spyridaki et al., 2012). Thus, macrolide antibiotics may help directly address the excess inflammation which drives morbidity in this population.

Inhaled antibiotics represent a safe mechanism to deliver high doses of targeted antibiotics to the lungs. Benefits in outpatients with targetable infections suggests the potential for a role in improving outcomes in mechanically ventilated patients. A meta-analysis of 5 RCTs examining the use of prophylactic aerosolized antibiotics (including gentamicin, ceftazidime, tobramycin, and polymyxin B) in mechanically ventilated patients found a reduced rate of nosocomial pneumonia in patients randomized to receive aerosolized antibiotics (Falagas et al., 2006). Interestingly, these trials did not include patients with asymptomatic colonization, who based on the CF/NCFBE data are most likely to show a benefit (Döring et al., 2012; Orriols et al., 2015). Future trials may explore the use of aerosolized antibiotics in mechanically ventilated patients colonized with PsA and other pathogens and further investigate the role of inhalational antibiotics for episodes of ventilator-associated pneumonias and pathogen eradication attempts.

Endpoints in Trials

The data presented herein demonstrates a plethora of chosen outcomes for both acute and chronic mechanical ventilation. Endpoints summarized in Table 1. Disparate outcomes without expert and scientific consensus pose a threat to definitive development of therapies aimed at mucoactive therapies in acutely ventilated patients. A recently conducted international consensus study outlined a set of core outcome measures that should be recorded in all clinical trials of interventions intended to modify the duration of ventilation for invasively mechanically ventilated patients in the ICU and included opinions from critical care physicians, ICU survivors, clinical trial investigators among others. These core outcomes included rates of extubation, reintubation, duration of mechanical ventilation, length of stay, health-related quality of life, and mortality (Blackwood et al., 2019). In addition to these variables, it would be prudent to propose that endpoints for the study of mucus clearance therapies in mechanically ventilated patients be grouped into sputum characteristics, physiologic endpoints, and patient-centered endpoints. Sputum characteristics to consider in clinical trials include sputum weight and density. Physiologic endpoints would include oxygenation (PaO2, pulse oximetry, and PaO2:FiO2), ventilation (PaCO2), ventilator physiology (peak and plateau airway pressures). Patient centered outcomes would include duration of mechanical ventilation, hospital length of stay, incidence of reintubation, occurrence of nosocomial pneumonia, and mortality. Determining appropriate clinical outcomes represents a challenge in this population given the significant heterogeneity of the patient population, poorly defined outcomes (including VAP), and difficulties identifying the best surrogate endpoints. However, since sputum characteristics, duration of mechanical ventilation, and reduction of VAP episodes seem most rigorously studied, we propose that these be a focus in developing therapies in the future from registry/observational studies to determine their role in surrogacy. Until further research is conducted, however, definitive conclusions from existing comparator studies will remain hampered in this patient population.

TABLE 1.

Summary of endpoints in various listed trials and their comparative outcomes.

Trial, first author Sputum Characteristics Respiratory physiology Ventilator physiology Duration of Mechanical ventilation Hospital/ICU length of stay Nosocomial pneumonia Mortality Need for Reintubation
rhDNase Altunhan et al., 2012
7% Hypertonic Saline+ rhDNase Altunhan et al., 2012
7% Hypertonic Saline Youness et al., 2012
rhDNase Youness et al., 2012
3% Hypertonic Saline Shein et al., 2016 #
N-acetyl cysteine Masoompour et al., 2015
rhDNase Zitter et al., 2013
rhDNase Pottecher et al., 2020 #
rhDNase Riethmueller et al., 2006
Cough Assist Ferreira de Camillis et al., 2018 #
HFCWO Kuyrukluyildiz et al., 2016
HFCWO Liu et al., 2014 #
HFCWO g (Chuang et al., 2017 #
HFCWO Clinkscale et al., 2012 #
IPV Clini et al., 2006 #
IPV Tsuruta et al., 2006
IPV Toussaint et al., 2003
IPV vs. HFCWO Bidiwala et al., 2017
Open in a new tab

Yellow: Intervention demonstrates benefit over comparator; Green: No difference in outcome between groups; Orange: Outcome worse in intervention Group; Gray: Measured but unclear (or pending) results, #: primary outcome.

Conclusion

Mucus clearance therapies form an essential part in the armamentarium available for the treatment of respiratory diseases associated with reduced or abnormal mucus clearance. Adoption of mucus clearance strategies in this critically ill population aims to break the self-propagating cycle of chronic inflammation/infections, and prevent extubation failures as a result of excessive tracheobronchial secretions. While both pharmacologic and non-pharmacologic modalities of airway clearance have been studied and are the standard of care in patients with CF and NCFBE, these interventions are still being explored as adjunctive therapeutic options in those requiring mechanical ventilation. Furthermore, trials conducted to date lack sufficient power, equipoise, and sufficient standardized endpoints to draw strong conclusions about therapy options. We postulate that it is beneficial to use mucoactive therapies in combination with cough augmentation strategies, however more studies with robust validation and standardized endpoints are needed to complement the existing expert recommendations.

Author Contributions

RG, KV, and GS contributed equally to composition and editing of the manuscript. All authors contributed to the article and approved the submitted version.

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Funding

GS declares funding provided by NIH (1K08HL138153-01A1 and 2P30DK072482-12) and CFF (GS 20Y0).

Supplementary Material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphys.2022.834716/full#supplementary-material

Click here for additional data file. (20.6KB, DOCX)

References

  1. Altunhan H., Annagür A., Pekcan S., Ors R., Koç H. (2012). Comparing the efficacy of nebulizer recombinant human DNase and hypertonic saline as monotherapy and combined treatment in the treatment of persistent atelectasis in mechanically ventilated newborns. Pediatr. Int. 54 131–136. 10.1111/j.1442-200X.2011.03519.x [DOI] [PubMed] [Google Scholar]
  2. Amitani R., Wilson R., Rutman A., Read R., Ward C., Burnett D., et al. (1991). Effects of human neutrophil elastase and Pseudomonas aeruginosa proteinases on human respiratory epithelium. Am. J. Respir. Cell Mol. Biol. 4 26–32. 10.1165/ajrcmb/4.1.26 [DOI] [PubMed] [Google Scholar]
  3. Anand R., McAuley D. F., Blackwood B., Yap C., ONeill B., Connolly B. (2020). Mucoactive agents for acute respiratory failure in the critically ill: a systematic review and meta-analysis. Thorax 75 623–631. 10.1136/thoraxjnl-2019-214355 [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Berger M., Sorensen R. U., Tosi M. F., Dearborn D. G., Döring G. (1989). Complement receptor expression on neutrophils at an inflammatory site, the Pseudomonas-infected lung in cystic fibrosis. J. Clin. Invest. 84 1302–1313. 10.1172/JCI114298 [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bidiwala A., Volpe L., Halaby C., Fazzari M., Valsamis C., Pirzada M. (2017). A comparison of high frequency chest wall oscillation and intrapulmonary percussive ventilation for airway clearance in pediatric patients with tracheostomy. Postgrad. Med. 129 276–282. 10.1080/00325481.2017.1264854 [DOI] [PubMed] [Google Scholar]
  6. Blackwood B., Ringrow S., Clarke M., Marshall J. C., Connolly B., Rose L., et al. (2019). A Core Outcome Set for Critical Care Ventilation Trials. Crit. Care Med. 47 1324–1331. 10.1097/CCM.0000000000003904 [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Chatburn R. L. (2007). High-frequency assisted airway clearance. Respir. Care 52 1224–1235. [PubMed] [Google Scholar]
  8. Chodhari R., Mitchison H. M., Meeks M. (2004). Cilia, primary ciliary dyskinesia and molecular genetics. Paediatr. Respir. Rev. 5 69–76. 10.1016/j.prrv.2003.09.005 [DOI] [PubMed] [Google Scholar]
  9. Chuang M. L., Chou Y. L., Lee C. Y., Huang S. F. (2017). Instantaneous responses to high-frequency chest wall oscillation in patients with acute pneumonic respiratory failure receiving mechanical ventilation: a randomized controlled study. Medicine 96:e5912. 10.1097/MD.0000000000005912 [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Clini E. M., Antoni F. D., Vitacca M., Crisafulli E., Paneroni M., Chezzi-Silva S., et al. (2006). Intrapulmonary percussive ventilation in tracheostomized patients: a randomized controlled trial. Intensive Care Med. 32 1994–2001. 10.1007/s00134-006-0427-8 [DOI] [PubMed] [Google Scholar]
  11. Clinkscale D., Spihlman K., Watts P., Rosenbluth D., Kollef M. H. (2012). A randomized trial of conventional chest physical therapy versus high frequency chest wall compressions in intubated and non-intubated adults. Respir. Care 57 221–228. 10.4187/respcare.01299 [DOI] [PubMed] [Google Scholar]
  12. Cole P. J. (1986). Inflammation: a two-edged sword–the model of bronchiectasis. Eur. J. Respir. Dis. Suppl. 147 6–15. [PubMed] [Google Scholar]
  13. Currie D. C., Saverymuttu S. H., Peters A. M., Needham S. G., George P., Dhillon D. P., et al. (1987). Indium-111-labelled granulocyte accumulation in respiratory tract of patients with bronchiectasis. Lancet 1 1335–1339. 10.1016/s0140-6736(87)90647-7 [DOI] [PubMed] [Google Scholar]
  14. Dentice R. L., Elkins M. R., Middleton P. G., Bishop J. R., Wark P. A., Dorahy D. J., et al. (2016). A randomised trial of hypertonic saline during hospitalisation for exacerbation of cystic fibrosis. Thorax 71 141–147. 10.1136/thoraxjnl-2014-206716 [DOI] [PubMed] [Google Scholar]
  15. Döring G., Flume P., Heijerman H., Elborn J. S. (2012). Treatment of lung infection in patients with cystic fibrosis: current and future strategies. J. Cyst. Fibros. 11 461–479. 10.1016/j.jcf.2012.10.004 [DOI] [PubMed] [Google Scholar]
  16. Ehre C., Rushton Z. L., Wang B., Hothem L. N., Morrison C. B., Fontana N. C., et al. (2019). An Improved Inhaled Mucolytic to Treat Airway Muco-obstructive Diseases. Am. J. Respir. Crit. Care Med. 199 171–180. 10.1164/rccm.201802-0245OC [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Elkins M. R., Bye P. T. (2011). Mechanisms and applications of hypertonic saline. J. R. Soc. Med. 104 S2–S5. 10.1258/jrsm.2011.s11101 [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Evans S. E., Xu Y., Tuvim M. J., Dickey B. F. (2010). Inducible innate resistance of lung epithelium to infection. Annu. Rev. Physiol. 72 413–435. 10.1146/annurev-physiol-021909-135909 [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Fahy J. V., Dickey B. F. (2010). Airway mucus function and dysfunction. N. Engl. J. Med. 363 2233–2247. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Falagas M. E., Siempos I. I., Bliziotis I. A., Michalopoulos A. (2006). Administration of antibiotics via the respiratory tract for the prevention of ICU-acquired pneumonia: a meta-analysis of comparative trials. Crit. Care 10:R123. 10.1186/cc5032 [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Feldman K. S., Kim E., Czachowski M. J., Wu Y., Lo C. W., Zahid M. (2021). Differential effect of anesthetics on mucociliary clearance in vivo in mice. Sci. Rep. 11:4896. 10.1038/s41598-021-84605-y [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Ferreira de Camillis M. L., Savi A., Goulart Rosa R, Figueiredo M., Wickert R., Borges L. G. A., et al. (2018). Effects of Mechanical Insufflation-Exsufflation on Airway Mucus Clearance Among Mechanically Ventilated ICU Subjects. Respir. Care 63 1471–1477. 10.4187/respcare.06253 [DOI] [PubMed] [Google Scholar]
  23. Gaga M., Bentley A. M., Humbert M., Barkans J., O’Brien F., Wathen C. G., et al. (1998). Increases in CD4+ T lymphocytes, macrophages, neutrophils and interleukin 8 positive cells in the airways of patients with bronchiectasis. Thorax 53 685–691. 10.1136/thx.53.8.685 [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Ganesan S., Comstock A. T., Sajjan U. S. (2013). Barrier function of airway tract epithelium. Tissue Barriers 1:e24997. 10.4161/tisb.24997 [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Giamarellos-Bourboulis E. J., Pechère J.-C., Routsi C., Plachouras D., Kollias S., Raftogiannis M., et al. (2008). Effect of Clarithromycin in Patients with Sepsis and Ventilator-Associated Pneumonia. Clin. Infect. Dis. 46 1157–1164. [DOI] [PubMed] [Google Scholar]
  26. Gobert F., Yonis H., Tapponnier R., Fernandez R., Labaune M. A., Burle J. F., et al. (2017). Predicting Extubation Outcome by Cough Peak Flow Measured Using a Built-in Ventilator Flow Meter. Respir. Care 62 1505–1519. 10.4187/respcare.05460 [DOI] [PubMed] [Google Scholar]
  27. Henke M. O., Ratjen F. (2007). Mucolytics in cystic fibrosis. Paediatr. Respir. Rev. 8 24–29. [DOI] [PubMed] [Google Scholar]
  28. Hirche T. O., Benabid R., Deslee G., Gangloff S., Achilefu S., Guenounou M., et al. (2008). Neutrophil elastase mediates innate host protection against Pseudomonas aeruginosa. J. Immunol. 181 4945–4954. 10.4049/jimmunol.181.7.4945 [DOI] [PubMed] [Google Scholar]
  29. Homnick D. N. (2007). Mechanical Insufflation-Exsufflation for Airway Mucus Clearance. Respir. Care 52 1296–1307. [PubMed] [Google Scholar]
  30. Jaber S., Quintard H., Cinotti R., Asehnoune K., Arnal J. M., Guitton C., et al. (2018). Risk factors and outcomes for airway failure versus non-airway failure in the intensive care unit: a multicenter observational study of 1514 extubation procedures. Crit. Care 22:236. 10.1186/s13054-018-2150-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Khamiees M., Raju P., DeGirolamo A., Amoateng-Adjepong Y., Manthous C. A. (2001). Predictors of extubation outcome in patients who have successfully completed a spontaneous breathing trial. Chest 120 1262–1270. 10.1378/chest.120.4.1262 [DOI] [PubMed] [Google Scholar]
  32. King M., Phillips D. M., Gross D., Vartian V., Chang H. K., Zidulka A. (1983). Enhanced tracheal mucus clearance with high frequency chest wall compression. Am. Rev. Respir. Dis. 128 511–515. 10.1164/arrd.1983.128.3.511 [DOI] [PubMed] [Google Scholar]
  33. King P., Bennett-Wood V., Hutchinson P., Robins-Browne R., Holmes P., Freezer N., et al. (2009). Bactericidal activity of neutrophils with reduced oxidative burst from adults with bronchiectasis. APMIS 117 133–139. 10.1111/j.1600-0463.2008.00028.x [DOI] [PubMed] [Google Scholar]
  34. Knowles M. R., Boucher R. C. (2002). Mucus clearance as a primary innate defense mechanism for mammalian airways. J. Clin. Invest. 109 571–577. 10.1172/JCI15217 [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Konrad F., Schreiber T., Brecht-Kraus D., Georgieff M. (1994). Mucociliary transport in ICU patients. Chest 105 237–241. 10.1378/chest.105.1.237 [DOI] [PubMed] [Google Scholar]
  36. Kuyrukluyildiz U., Binici O., Kupeli I., Erturk N., Gulhan B., Akyol F. (2016). What Is the Best Pulmonary Physiotherapy Method in ICU?. Can. Respir. J. 2016:4752467. 10.1155/2016/4752467 [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Lange D. J., Lechtzin N., Davey C., David W., Heiman-Patterson T., Gelinas D., et al. (2006). High-frequency chest wall oscillation in ALS: an exploratory randomized, controlled trial. Neurology 67 991–997. 10.1212/01.wnl.0000237439.78935.46 [DOI] [PubMed] [Google Scholar]
  38. Liu T., Kang Y., Xu Z., Lyu Y., Jia L., Gao Y. (2014). [A study of the value of high frequency chest wall oscillation in patients with acute exacerbation of chronic obstructive pulmonary disease]. Zhonghua Jie He He Hu Xi Za Zhi 37 255–259. [PubMed] [Google Scholar]
  39. Locke L. W., Myerburg M. M., Weiner D. J., Markovetz M. R., Parker R. S., Muthukrishnan A., et al. (2016). Pseudomonas infection and mucociliary and absorptive clearance in the cystic fibrosis lung. Eur. Respir. J. 47 1392–1401. 10.1183/13993003.01880-2015 [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Maggiore S. M., Battilana M., Serano L., Petrini F. (2018). Ventilatory support after extubation in critically ill patients. Lancet Respir. Med. 6 948–962. 10.1016/S2213-2600(18)30375-8 [DOI] [PubMed] [Google Scholar]
  41. Masoompour S. M., Anushiravani A., Tafaroj Norouz A. (2015). Evaluation of the Effect of Nebulized N-Acetylcysteine on Respiratory Secretions in Mechanically Ventilated Patients: randomized Clinical Trial. Iran. J. Med. Sci. 40 309–315. [PMC free article] [PubMed] [Google Scholar]
  42. McCoy K., Hamilton S., Johnson C. (1996). Effects of 12-week administration of dornase alfa in patients with advanced cystic fibrosis lung disease. Pulmozyme Study Group. Chest 110 889–895. 10.1378/chest.110.4.889 [DOI] [PubMed] [Google Scholar]
  43. Mikami M., Llewellyn-Jones C. G., Bayley D., Hill S. L., Stockley R. A. (1998). The chemotactic activity of sputum from patients with bronchiectasis. Am. J. Respir. Crit. Care Med. 157 723–728. 10.1164/ajrccm.157.3.9606120 [DOI] [PubMed] [Google Scholar]
  44. Munkholm M., Mortensen J. (2014). Mucociliary clearance: pathophysiological aspects. Clin. Physiol. Funct. Imaging 34 171–177. 10.1111/cpf.12085 [DOI] [PubMed] [Google Scholar]
  45. Natale J. E., Pfeifle J., Homnick D. N. (1994). Comparison of intrapulmonary percussive ventilation and chest physiotherapy. A pilot study in patients with cystic fibrosis. Chest 105 1789–1793. 10.1378/chest.105.6.1789 [DOI] [PubMed] [Google Scholar]
  46. Orriols R., Hernando R., Ferrer A., Terradas S., Montoro B. (2015). Eradication Therapy against Pseudomonas aeruginosa in Non-Cystic Fibrosis Bronchiectasis. Respiration 90 299–305. [DOI] [PubMed] [Google Scholar]
  47. Paul K., Rietschel E., Ballmann M., Griese M., Worlitzsch D., Shute J., et al. (2004). Effect of treatment with dornase alpha on airway inflammation in patients with cystic fibrosis. Am. J. Respir. Crit. Care Med. 169 719–725. 10.1164/rccm.200307-959OC [DOI] [PubMed] [Google Scholar]
  48. Pittet L. A., Hall-Stoodley L., Rutkowski M. R., Harmsen A. G. (2010). Influenza virus infection decreases tracheal mucociliary velocity and clearance of Streptococcus pneumoniae. Am. J. Respir. Cell Mol. Biol. 42 450–460. 10.1165/rcmb.2007-0417OC [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Pottecher J., Noll E., Borel M., Audibert G., Gette S., Meyer C., et al. (2020). Protocol for TRAUMADORNASE: a prospective, randomized, multicentre, double-blinded, placebo-controlled clinical trial of aerosolized dornase alfa to reduce the incidence of moderate-to-severe hypoxaemia in ventilated trauma patients. Trials 21:274. 10.1186/s13063-020-4141-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Qi Q., Ailiyaer Y., Liu R., Zhang Y., Li C., Liu M., et al. (2019). Effect of N-acetylcysteine on exacerbations of bronchiectasis (BENE): a randomized controlled trial. Respir. Res. 20:73. 10.1186/s12931-019-1042-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Quan J. M., Tiddens H. A., Sy J. P., McKenzie S. G., Montgomery M. D., Robinson P. J., et al. (2001). A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities. J. Pediatr. 139 813–820. 10.1067/mpd.2001.118570 [DOI] [PubMed] [Google Scholar]
  52. Ratjen F., Paul K., van Koningsbruggen S., Breitenstein S., Rietschel E., Nikolaizik W. (2005). DNA concentrations in BAL fluid of cystic fibrosis patients with early lung disease: influence of treatment with dornase alpha. Pediatr. Pulmonol. 39 1–4. 10.1002/ppul.20134 [DOI] [PubMed] [Google Scholar]
  53. Ray J. F., III, Yost L., Moallem S., Sanoudos G. M., Villamena P., Paredes R. M., et al. (1974). Immobility, hypoxemia, and pulmonary arteriovenous shunting. Arch. Surg. 109 537–541. 10.1001/archsurg.1974.01360040055014 [DOI] [PubMed] [Google Scholar]
  54. Riethmueller J., Borth-Bruhns T., Kumpf M., Vonthein R., Wiskirchen J., Stern M., et al. (2006). Recombinant human deoxyribonuclease shortens ventilation time in young, mechanically ventilated children. Pediatr. Pulmonol. 41 61–66. 10.1002/ppul.20298 [DOI] [PubMed] [Google Scholar]
  55. Rogers D. F. (2007). Mucoactive agents for airway mucus hypersecretory diseases. Respir. Care 52 1176–1193. [PubMed] [Google Scholar]
  56. Rosière J., Vader J. P., Cavin M. S., Grant K., Larcinese A., Voellinger R., et al. (2009). Appropriateness of respiratory care: evidence-based guidelines. Swiss Med. Wkly. 139 387–392. [DOI] [PubMed] [Google Scholar]
  57. Rubin B. K. (2014). Secretion properties, clearance, and therapy in airway disease. Transl. Respir. Med. 2:6. 10.1186/2213-0802-2-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. Sackner M. A., Hirsch J., Epstein S. (1975a). Effect of cuffed endotracheal tubes on tracheal mucous velocity. Chest 68 774–777. 10.1378/chest.68.6.774 [DOI] [PubMed] [Google Scholar]
  59. Sackner M. A., Landa J., Hirsch J., Zapata A. (1975b). Pulmonary effects of oxygen breathing. A 6-hour study in normal men. Ann. Intern. Med. 82 40–43. 10.7326/0003-4819-82-1-40 [DOI] [PubMed] [Google Scholar]
  60. Schweickert W. D., Hall J. (2007). ICU-acquired weakness. Chest 131 1541–1549. [DOI] [PubMed] [Google Scholar]
  61. Shah S., Fung K., Brim S., Rubin B. K. (2005). An in vitro evaluation of the effectiveness of endotracheal suction catheters. Chest 128 3699–3704. 10.1378/chest.128.5.3699 [DOI] [PubMed] [Google Scholar]
  62. Sheffner A. L., Medler E. M., Jacobs L. W., Sarett H. P. (1964). The In Vitro Reduction In Viscosity Of Human Tracheobronchial Secretions By Acetylcysteine. Am. Rev. Respir. Dis. 90 721–729. 10.1164/arrd.1964.90.5.721 [DOI] [PubMed] [Google Scholar]
  63. Shein S. L., Gallagher J. T., Deakins K. M., Weinert D. M. (2016). Prophylactic Use of Nebulized Hypertonic Saline in Mechanically Ventilated Children: a Randomized Blinded Pilot Study. Respir. Care 61 586–592. 10.4187/respcare.04418 [DOI] [PubMed] [Google Scholar]
  64. Smina M., Salam A., Khamiees M., Gada P., Amoateng-Adjepong Y., Manthous C. A. (2003). Cough peak flows and extubation outcomes. Chest 124 262–268. 10.1378/chest.124.1.262 [DOI] [PubMed] [Google Scholar]
  65. Spyridaki A., Raftogiannis M., Antonopoulou A., Tsaganos T., Routsi C., Baziaka F., et al. (2012). Effect of clarithromycin in inflammatory markers of patients with ventilator-associated pneumonia and sepsis caused by Gram-negative bacteria: results from a randomized clinical study. Antimicrob. Agents Chemother. 56 3819–3825. 10.1128/AAC.05798-11 [DOI] [PMC free article] [PubMed] [Google Scholar]
  66. Thille A. W., Boissier F., Ben Ghezala H., Razazi K., Mekontso-Dessap A., Brun-Buisson C. (2015). Risk factors for and prediction by caregivers of extubation failure in ICU patients: a prospective study. Crit. Care Med. 43 613–620. 10.1097/CCM.0000000000000748 [DOI] [PubMed] [Google Scholar]
  67. Toussaint M., De Win H., Steens M., Soudon P. (2003). Effect of intrapulmonary percussive ventilation on mucus clearance in duchenne muscular dystrophy patients: a preliminary report. Respir. Care 48 940–947. [PubMed] [Google Scholar]
  68. Tsuruta R., Kasaoka S., Okabayashi K., Maekawa T. (2006). Efficacy and safety of intrapulmonary percussive ventilation superimposed on conventional ventilation in obese patients with compression atelectasis. J. Crit. Care 21 328–332. 10.1016/j.jcrc.2006.03.008 [DOI] [PubMed] [Google Scholar]
  69. van Delden C., Köhler T., Brunner-Ferber F., François B., Carlet J., Pechère J.-C. (2012). Azithromycin to prevent Pseudomonas aeruginosa ventilator-associated pneumonia by inhibition of quorum sensing: a randomized controlled trial. Intensive Care Med.. 38 1118–1125. 10.1007/s00134-012-2559-3 [DOI] [PubMed] [Google Scholar]
  70. Verleden G. M., Vanaudenaerde B. M., Dupont L. J., Van Raemdonck D. E. (2006). Azithromycin reduces airway neutrophilia and interleukin-8 in patients with bronchiolitis obliterans syndrome. Am. J. Respir. Crit. Care Med. 174 566–570. 10.1164/rccm.200601-071OC [DOI] [PubMed] [Google Scholar]
  71. Wanner A., Salathé M., O’Riordan T. G. (1996). Mucociliary clearance in the airways. Am. J. Respir. Crit. Care Med. 154 1868–1902. 10.1164/ajrccm.154.6.8970383 [DOI] [PubMed] [Google Scholar]
  72. Warwick W. J., Hansen L. G. (1991). The long-term effect of high-frequency chest compression therapy on pulmonary complications of cystic fibrosis. Pediatr. Pulmonol. 11 265–271. 10.1002/ppul.1950110314 [DOI] [PubMed] [Google Scholar]
  73. Watt A. P., Brown V., Courtney J., Kelly M., Garske L., Elborn J. S., et al. (2004). Neutrophil apoptosis, proinflammatory mediators and cell counts in bronchiectasis. Thorax 59 231–236. 10.1136/thx.2003.008037 [DOI] [PMC free article] [PubMed] [Google Scholar]
  74. Widdicombe J. H., Wine J. J. (2015). Airway Gland Structure and Function. Physiol. Rev. 95 1241–1319. 10.1152/physrev.00039.2014 [DOI] [PubMed] [Google Scholar]
  75. Youness H. A., Mathews K., Elya M. K., Kinasewitz G. T., Keddissi J. I. (2012). Dornase alpha compared to hypertonic saline for lung atelectasis in critically ill patients. J. Aerosol. Med. Pulm. Drug Deliv. 25 342–348. 10.1089/jamp.2011.0954 [DOI] [PubMed] [Google Scholar]
  76. Zahm J. M., King M., Duvivier C., Pierrot D., Girod S., Puchelle E. (1991). Role of simulated repetitive coughing in mucus clearance. Eur. Respir. J. 4 311–315. [PubMed] [Google Scholar]
  77. Zanin M., Baviskar P., Webster R., Webby R. (2016). The Interaction between Respiratory Pathogens and Mucus. Cell Host Microbe 19 159–168. 10.1016/j.chom.2016.01.001 [DOI] [PMC free article] [PubMed] [Google Scholar]
  78. Zhou-Suckow Z., Duerr J., Hagner M., Agrawal R., Mall M. A. (2017). Airway mucus, inflammation and remodeling: emerging links in the pathogenesis of chronic lung diseases. Cell Tissue Res. 367 537–550. 10.1007/s00441-016-2562-z [DOI] [PubMed] [Google Scholar]
  79. Zitter J. N., Maldjian P., Brimacombe M., Fennelly K. P. (2013). Inhaled Dornase alfa (Pulmozyme) as a noninvasive treatment of atelectasis in mechanically ventilated patients. J. Crit. Care 28 218.e1–7. 10.1016/j.jcrc.2012.09.015 [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Click here for additional data file. (20.6KB, DOCX)

Articles from Frontiers in Physiology are provided here courtesy of Frontiers Media SA

RESOURCES